隴神戎發(300534.SZ):擬向控股股東及其一致行動人定增募資不超過4.86億元
格隆匯7月17日丨隴神戎發(300534.SZ)公佈,擬向特定對象發行A股股票擬募集資金總額不超過4.86億元,扣除發行費用後全部用於甘肅普安製藥股份有限公司年產5000萬盒(3億支)宣肺止嗽合劑等液體制劑生產線升級改造項目、甘肅隴神戎發藥業股份有限公司三化改造及合劑生產線配套建設項目、補充流動資金及償還貸款。控股股東甘肅藥業集團擬認購數量不超過本次發行新股數量的30.79%,認購金額不超過14,955.82萬元;一致行動人絲路基金擬認購數量為本次發行新股數量的7.11%,認購金額不超過3,454.02萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.